Email this article The effect of surgical treatment on the quality of life of kidney cancer patients with single bone metastases
- Authors: Kostritsky S.V.1, Shirokorad V.I.1, Alekseev B.Y.2,3, Semenov D.V.4,5, Kalpinsky A.S.6, Korneva Y.S.7,8,9
-
Affiliations:
- Moscow City Oncological Hospital
- National Medical Research Radiological Center
- Russian Biotechnological University
- City Clinical Oncology Dispensary
- Saint Petersburg State University
- P.A. Herzen Moscow Research Oncological Institute, National Medical Research Radiological Center
- Smolensk State Medical University
- North-Western State Medical University named after I.I. Mechnikov
- City Hospital No. 26
- Issue: Vol 13, No 2 (2023)
- Pages: 117-126
- Section: Original articles
- URL: https://bakhtiniada.ru/uroved/article/view/134251
- DOI: https://doi.org/10.17816/uroved321265
- ID: 134251
Cite item
Open Access
Access granted
Subscription Access
Abstract
BACKGROUND: Renal cell cancer is complicated with bone metastases quite often, which are determined in a third of patients at the time of diagnosis of the primary tumor. The development of skeletal complications causes the complexity of managing such patients, which requires optimizing treatment tactics using combined methods and improving the quality of life after treatment.
AIM: The aim of this study is to assess the quality of life of renal cell cancer patients with single metastases in the bones before and after surgical treatment in combination with targeted therapy and without it.
MATERIALS AND METHODS: The study included 62 patients with single bone metastases of renal cell cancer with the presence of skeletal related events. 20 patients (group 1) underwent surgical treatment of metastases after surgery on the primary focus in combination with targeted therapy, 42 patients (group 2) underwent only surgical treatment of metastases. The quality of life was assessed using the EORTC QLQ-C30 questionnaire before and after surgery within and between groups.
RESULTS: Comparison of the survey influence on life quality in group 1 before and after treatment revealed that 8 out of 30 indicators of the EORTC QLQ-C30 questionnaire did not show a statistically significant change. These include: any restrictions in daily activities, as well as doing what you like, decreased appetite, nausea, shortness of breath, diarrhea, fatigue, financial difficulties. The remaining 22 indicators of the scale showed a statistically significant improvement. Comparison of quality of life indicators in group 2 before and after treatment showed that for 3 out of 30 indicators of the EORTC QLQ-C30 questionnaire, no statistically significant changes were registered, among them: the severity of pain syndrome, the presence of financial difficulties and health status over the past week. Statistically significant improvement was revealed for the remaining 27 indicators of the scale. Prior to treatment, difficulties in taking a short walk, doing daily chores, doing favorite things are more pronounced in group 1, and the need for rest in group 2 patients. After surgery, the indicators associated with daily activity were worse in group 1 patients, while the severity of the pain syndrome, its effect on daily activity, the need for rest, a sense of tension, and the effect on the emotional background were more noticeable in group 2 patients. Both before and after surgery, group 1 patients had a better assessment of both their health and quality of life over the past week.
CONCLUSIONS: The comparative analysis of the treatment confirmed our hypothesis that the most rational and effective combination is an active surgical tactic in combination with targeted therapy for bone oligometastases of renal cell cancer.
Full Text
##article.viewOnOriginalSite##About the authors
Stanislav V. Kostritsky
Moscow City Oncological Hospital
Author for correspondence.
Email: stas.medic@bk.ru
ORCID iD: 0000-0003-4494-1489
SPIN-code: 1421-2469
oncourologist
Russian Federation, Istra settlement, Krasnogorsk District, Moscow RegionValery I. Shirokorad
Moscow City Oncological Hospital
Email: shirokorad@bk.ru
ORCID iD: 0000-0003-4109-6451
MD, Dr. Sci. (Med.), head of the Oncourological Unit
Russian Federation, Istra settlement, Krasnogorsk District, Moscow RegionBoris Ya. Alekseev
National Medical Research Radiological Center; Russian Biotechnological University
Email: byalekseev@mail.ru
ORCID iD: 0000-0002-3398-4128
SPIN-code: 4692-5705
Scopus Author ID: 16023947400
MD, Dr. Sci. (Med.), Professor, Deputy General Director for Research, head of Department of Oncology, Medical Institute of Continuing Education
Russian Federation, Moscow; MoscowDmitry V. Semenov
City Clinical Oncology Dispensary; Saint Petersburg State University
Email: sema.69@mail.ru
ORCID iD: 0000-0002-4335-8446
MD, Cand. Sci. (Med.), oncourologist, assistant professor in the Department of Oncology, Medical Institute
Russian Federation, Saint Petersburg; Saint PetersburgAleksey S. Kalpinsky
P.A. Herzen Moscow Research Oncological Institute, National Medical Research Radiological Center
Email: dr.kalpinskiytrial@gmail.com
ORCID iD: 0000-0002-2209-3020
SPIN-code: 7253-9356
Scopus Author ID: 57192806201
MD, Cand. Sci. (Med.), senior research associate, urologist, Department of Tumors of the Reproductive and Urinary Organs
Russian Federation, MoscowYulia S. Korneva
Smolensk State Medical University; North-Western State Medical University named after I.I. Mechnikov; City Hospital No. 26
Email: ksu1546@yandex.ru
ORCID iD: 0000-0002-8080-904X
SPIN-code: 5169-7740
Scopus Author ID: 56657493900
Cand. Sci. (Med.), assistant professor of the Department of Pathological Anatomy, pathologist
Russian Federation, Smolensk; Saint Petersburg; Saint PetersburgReferences
- Dudani S, de Velasco G, Wells JC, et al. Evaluation of clear cell, papillary, and chromophobe renal cell carcinoma metastasis sites and association with survival. JAMA Netw Open. 2021;4(1): e2021869. doi: 10.1001/jamanetworkopen.2020.21869
- Wood SL, Brown JE. Skeletal metastasis in renal cell carcinoma: current and future management options. Cancer Treat Rev. 2012;38(4):284–291. doi: 10.1016/j.ctrv.2011.06.011
- Owari T, Miyake M, Nakai Y, et al. Clinical features and risk factors of skeletal-related events in genitourinary cancer patients with bone metastasis: A retrospective analysis of prostate cancer, renal cell carcinoma, and urothelial carcinoma. Oncology. 2018;95(3): 170–178. doi: 10.1159/000489218
- Mottet N, Bellmunt J, Bolla M, et al. EAU-ESTRO-SIOG guidelines on prostate cancer. Part 1: Screening, diagnosis, and local treatment with curative Intent. Eur Urol. 2017;71(4):618–629. doi: 10.1016/j.eururo.2016.08.003
- Semkov AS, Makhson AN, Peterson SB, et al. Surgical treatment for bone metastases of kidney cancer. Oncourologia. 2010;6(4): 10–15. (In Russ.) doi: 10.17650/1726-9776-2010-6-4-10-15
- Mendez LC, Raman S, Wan BA, et al. Quality of life in responders after palliative radiation therapy for painful bone metastases using EORTC QLQ-C30 and EORTC QLQ-BM22: results of a Brazilian cohort. Ann Palliat Med. 2017;6(Suppl 1): S65–S70. doi: 10.21037/apm.2017.04.06
- Azawi NH, Tesfalem H, Dahl C, Lund L. Do the different types of renal surgery impact the quality of life in the postoperative period? Int Urol Nephrol. 2015;47(2):263–269. doi: 10.1007/s11255-014-0893-9
- Zhao W, Wang H, Hu JH, et al. Palliative pain relief and safety of percutaneous radiofrequency ablation combined with cement injection for bone metastasis. Jpn J Clin Oncol. 2018;48(8):753–759. doi: 10.1093/jjco/hyy090
- Herrmann E, Gerss J, Bierer S, et al. Pre-treatment global quality of health predicts progression free survival in metastatic kidney cancer patients treated with sorafenib. J Cancer Res Clin Oncol. 2009;135(1):61–67. doi: 10.1007/s00432-008-0438-7
Supplementary files
